nitrendipine has been researched along with Recrudescence in 4 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality." | 9.11 | Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). ( Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W, 2005) |
| "Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension." | 8.85 | Eprosartan: a review of its use in hypertension. ( Plosker, GL, 2009) |
| "In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality." | 5.11 | Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). ( Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W, 2005) |
| "Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension." | 4.85 | Eprosartan: a review of its use in hypertension. ( Plosker, GL, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trouillier, HH | 1 |
| Birkenmaier, C | 1 |
| Seidl, T | 1 |
| Jansson, V | 1 |
| Plosker, GL | 1 |
| Schrader, J | 1 |
| Lüders, S | 1 |
| Kulschewski, A | 1 |
| Hammersen, F | 1 |
| Plate, K | 1 |
| Berger, J | 1 |
| Zidek, W | 1 |
| Dominiak, P | 1 |
| Diener, HC | 1 |
| Owen, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nitrendipine and Recrudescence
| Article | Year |
|---|---|
Eprosartan: a review of its use in hypertension.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Ma | 2009 |
2 trials available for nitrendipine and Recrudescence
| Article | Year |
|---|---|
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; B | 2005 |
MOSES: superiority or noninferiority?
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2006 |
1 other study available for nitrendipine and Recrudescence
| Article | Year |
|---|---|
Complications following kyphoplasty in unstable osteoporotic vertebral body fractures. A guide to correct fracture analysis.
Topics: Humans; Kyphoplasty; Nitrendipine; Osteoporotic Fractures; Postoperative Complications; Radiography; | 2013 |